Quantum Genomics approves strategic tie-up with ExactCure

Quantum Genomics announced the approval by its shareholders of the operations to reduce its share capital and the contribution in kind of ExactCure shares. The General Assembly, held on April 24, 2024, validated these decisions with an overwhelming majority of 99.88% for each resolution. This marks a crucial turning point in the strategic alignment with ExactCure, a HealthTech company specializing in the adaptation of medication to the individual profile via artificial intelligence.

This strategic merger saw a capital reduction at Quantum Genomics, lowering the par value of a share to around 0.04 euros, followed by an increase due to the contribution of ExactCure securities, valued at 6 million euros. euros. As a result, Quantum Genomics issues 34,854,973 new shares, thus increasing its share capital to 2,787,137.94 euros. Quantum Genomics now owns 100% of ExactCure, solidifying its position in the market.